Incircular BV was founded by three (bio)chemists at VU Amsterdam who have developed a novel technology for stabilizing proteins: INCYPRO. In their recently launched spin-off, Saskia Neubacher, Sven Hennig and Tom Grossmann will use this technology to stabilize proteins for applications in drug development, diagnostic testing, and biocatalysis.
Proteins are a class of large, natural molecules produced in all organisms. They include enzymes, antibodies, hormones and many more, and are involved in all cellular processes. The 3D structure of proteins is essential for their specific function and performance but many proteins lose their function outside of the natural environment because their 3D structure is fragile. This led the VU Amsterdam scientists to develop the INCYPRO protein stabilization technology. INCYPRO supports the natural 3D structure of proteins through a design process that enables the precise chemical modification of a protein and thus allows novel applications.
The development of novel drugs
Most drugs on the market today target disease-associated proteins. To enable an efficient drug development process for currently untreatable diseases, such as Alzheimer’s disease and cancer, it is important to isolate the disease-associated proteins for in-depth analysis and screening. INCYPRO-stabilized proteins can thus be very useful for the development of safe and efficient novel drugs. Incircular will use the INCYPRO technology to deliver solutions for its clients, which include companies in the pharmaceutical sector whose applications are adversely impacted by the instability of their proteins. The company provides these clients with robust proteins that they need to facilitate their application. Neubacher: “The INCYPRO technology has the potential to enable the discovery of future drugs. It would be truly amazing if our work could improve the quality of life of many patients.”
The scientists from the Department of Chemistry & Pharmaceutical Sciences and the Amsterdam Institute of Molecular & Life Sciences launched their new company under the guidance of Innovation Exchange Amsterdam (IXA) and the Demonstrator Lab. In addition, the team of scientists has received funding from the Dutch Research Council (NWO) and the European Research Council (ERC). In 2019, the INCYPRO technology reached the finals of the competition for the Amsterdam Science & Innovation Award.
Following the tremendous success of the Demonstrator Lab at the VU campus, the Amsterdam knowledge institutes have decided to launch a new location at Amsterdam Science Park. The new location will be situated in the heart of the UvA Faculty of Science’s laboratories, on the ground floor of building D. The reconstruction of the lab […]News
Fitsurance was awarded RVO MIT feasibility subsidy from Provincie Noord Holland. With this subsidy Fitsurance will investigate the feasibility of a Reinforcement Learning system that analyzes the best method to motivate someone to exercise more. The software is intended for patients with a metabolic disease and for healthy people to prevent metabolic diseases. The feasibility […]News
VU spin-off Incircular received a €300,000 convertible loan from Noord-Holland Innovation Fund. With the loan, Incircular will further develop its INCYPRO technology to stabilize proteins for applications in research and drug discovery. Proteins perform a plethora of essential tasks with unparalleled efficiency and specificity within every organism. It is these properties that have driven scientists […]News